Clinical trial
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
NCT00319137 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00319137 |
|---|---|
| Title | An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine |
| Official title | A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of Doses of 5-180 mg of the iNOS Inhibitor GW274150 in the Treatment of Acute Migraine During the Mild Headache Phase |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Migraine Disorders, Migraine |
| Intervention type | Drug |
| Interventions | GW274150 |
| Enrollment | 126 |
| Start date | Dec 1, 2005 |
| First posted | Apr 27, 2006 |
| Last update posted | Jun 4, 2012 |
| Countries | Australia, New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: